CompletedNot Applicable

PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Japan52 participantsStarted 2023-04-18

Plain-language summary

Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * GPP patients with acute symptoms who are administered Spesolimab Intravenous (I.V.) Infusion in Japan * Patients who have never been treated with Spesolimab I.V. Infusion before enrolment Exclusion Criteria: * None

What they're measuring

Incidence of adverse drug reactions (ADRs)

Timeframe: Up to 36 weeks

Trial details

NCT IDNCT05670821

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-10-06

View on ClinicalTrials.gov More Generalized Pustular Psoriasis trials